Skip to main content

Poorly Differentiated Thyroid Gland Carcinoma clinical trials at UCSD
2 research studies open to new patients

  • Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

    open to eligible people ages 18 years and up

    This randomized phase II trial studies how well iodine I-131 works with or without selumetinib in treating patients with thyroid cancer that has returned or has spread from where it started to other places in the body. Many thyroid cancers absorb iodine. Due to this, doctors often give radioactive iodine (iodine I-131) alone to treat thyroid cancer as part of standard practice. It is thought that the more thyroid tumors are able to absorb radioactive iodine, the more likely it is that the radioactive iodine will cause those tumors to shrink. Selumetinib may help radioactive iodine work better in patients whose tumors still absorb radioactive iodine. It is not yet known whether iodine I-131 is more effective with or without selumetinib in treating thyroid cancer.

    La Jolla, California and other locations

  • Lenvatinib and Pembrolizumab in DTC

    open to eligible people ages 18 years and up

    This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may stimulate the immune system to attack the cancer, and kinase inhibitors, such as lenvatinib, may interfere with the ability of tumor cells to grow and spread.

    La Jolla, California and other locations

Last updated: